The Impact of Dual Antiplatelet Therapy Guided by Platelet Function Testing on the Prognosis of Patients With Dual High-Risk Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Reviews in Cardiovascular Medicine · 11.02.2026 · 27 (2)
DOI: 10.31083/rcm41544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 11.02.2026. Verfasst von Mengjie Lei und 7 weiteren Autor:innen. Beteiligte Einrichtung: Langfang Core Laboratory of Precision Treatment of coronary artery disease, Langfang People's Hospital, 065000 Langfang, Hebei, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Science Research Project of Hebei.
Abstract (Originalsprache)
Background
To investigate the effect of dual antiplatelet therapy (DAPT) guided by platelet function testing (PFT) on the prognosis of patients with acute coronary syndrome (ACS) at a high risk for ischemia and bleeding who underwent percutaneous coronary intervention (PCI).
Methods
A retrospective analysis was conducted on 1816 patients with ACS and a dual high risk who underwent PCI at a single center from March 2017 to November 2022. Patients were stratified into the guided DAPT group (n = 712) and standard DAPT group (n = 1104) according to whether the patient received PFT. All patients received oral DAPT for a duration of 12 months post-PCI. The deadline for the endpoint was within 12 months of receiving PCI. The primary endpoint was the number of net clinical adverse events (NACEs) that occurred during follow-up, including the composite endpoint of major adverse cardiovascular and cerebrovascular events (MACCEs) and bleeding, as defined by the bleeding academic research consortium (BARC) (type 3 or greater).
Results
Compared with the standard DAPT group, the guided DAPT group exhibited a lower incidence of NACEs (4.8% vs. 8.7%; p = 0.001), MACCEs (3.9% vs. 6.7%; p = 0.017), cardiac death (0.4% vs. 1.5%; p = 0.038), and stroke (0.6% vs. 2.5%; p = 0.005) during follow-up. Cox regression analysis revealed that the incidence of NACEs (hazard ratio (HR): 0.543, 95% confidence interval (CI): 0.363–0.812; p = 0.003), MACCEs (HR: 0.570, 95% CI: 0.364–0.893; p = 0.014), cardiac death (HR: 0.249, 95% CI: 0.072–0.866; p = 0.029), and stroke (HR: 0.174, 95% CI: 0.060–0.501; p = 0.001) in the guided DAPT group was 0.543, 0.570, 0.249, and 0.174 times, respectively, that in the standard DAPT group.
Conclusion
For patients with ACS who are at high risk in the East Asian population, the primary recommendation is to use PFT to guide DAPT within 12 months after PCI, which can reduce the incidence of NACEs, primarily by lowering the rate of MACCEs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Langfang Core Laboratory of Precision Treatment of coronary artery disease, Langfang People's Hospital, 065000 Langfang, Hebei, China.
ORCID-Profile: Mengjie Lei, Zengming Xue
Förderung
- Medical Science Research Project of Hebei
Zitieren
APA
Lei, M., Li, Y., Wang, J., Sun, X., Li, C., Wang, X., Zhao, Z., & Xue, Z. (2026). The Impact of Dual Antiplatelet Therapy Guided by Platelet Function Testing on the Prognosis of Patients With Dual High-Risk Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Reviews in Cardiovascular Medicine, 27(2). https://doi.org/10.31083/rcm41544
Vancouver
Lei M, Li Y, Wang J, Sun X, Li C, Wang X, et al. The Impact of Dual Antiplatelet Therapy Guided by Platelet Function Testing on the Prognosis of Patients With Dual High-Risk Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Reviews in Cardiovascular Medicine. 2026;27(2). doi:10.31083/rcm41544
BibTeX
@article{Lei2026,
author = {Lei, Mengjie and Li, Yachao and Wang, Jingyao and Sun, Xue and Li, Cairong and Wang, Xiao and Zhao, Zhigang and Xue, Zengming},
title = {The Impact of Dual Antiplatelet Therapy Guided by Platelet Function Testing on the Prognosis of Patients With Dual High-Risk Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
volume = {27},
number = {2},
doi = {10.31083/rcm41544}
}
EUVIMED